Year end report 2003
Tripep AB (publ)-Year-end Report 2003 · Loss after tax for the full year 2003: SEK -13.0 million (SEK - 42.5 m). Research and development costs for the full year 2003: SEK 12.4 million (SEK 13.8 m). The company has yet to generate any operating income, and accordingly has no net sales. EPS for the full year 2003: SEK -1.00 (-3.07). · Research associated with GPG's metabolite (previous working title: MetaboliteX = 'Metabolite Unknown') has resulted in the discovery of the antiviral substance alfaHGA, and a patent application has been filed for its structure. A chemical synthesis method has been devised. · Clinical trials of alfaHGA on humans are planned for the first half-year 2004. · The first presentation of alfaHGA will be at the 5th Antiviral Drug Discovery & Development Summit on 29 - 30 March 2004 at Cherry Hill, NJ, US. · Tripep incorporated the biotech enterprise VLP Biotech Inc. in San Diego alongside US researchers; Tripep's holding is 30%. The company's first intended product is a universal influenza vaccine. · The Swedish Industrial Development Fund has permitted remission of SEK 10 m of its SEK 20 m conditional loan for the development of GPG. This implies that the company is now free of debt. · Tripep's Board of Directors is currently examining the benefits and consequences of parallel quotation on the London-based AIM (Alternative Investment Market). · After the end of the period, Tripep secured a US patent for a new application of its antiviral substance ribavirin. For more information, please contact Johan Ihre, CEO Tel: +46 (0)8 449 8480, mobile: +46 (0)70 733 4425 e-mail: johan.ihre@tripep.se or Anders Vahlne, Vice President, Research Tel: +46 (0)8 585 81313, mobile: +46 (0)70 928 0528 e-mail: anders.vahlne@labmed.ki.se Tripep is a biotech research company that develops and commercialises - research and development of alfaHGA, a potential HIV-inhibiting drug, - preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. - producing vaccines against influenza, allergies and Alzheimer's Disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se Tripep AB (publ.) Hälsovägen 7 S-141 57 Huddinge Sweden Tel: +46 (0)8 449 8480 Corp. ID. No.: 556541-1898 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/01/30/20040130BIT00250/wkr0001.doc The full report http://www.waymaker.net/bitonline/2004/01/30/20040130BIT00250/wkr0002.pdf The full report